Recent systemic review and meta-analysis demonstrated, that treatment with functional agonists of GLP-1 which included both GLP-1RAs and DPP4 inhibitors resulted in a significant reduction of depression rating scores and tended to be superior over control treatments, which supports the hypothesis of their antidepressant action in humans. Here, GCG is linked to depressive disorder.